ADA's updated standards of diabetes care include recommendations for hypertension, screening high-risk youth
The American Diabetes Association (ADA)'s 2018 update also recommends that adults with type 2 diabetes and heart disease receive a medication proven to improve heart health, after lifestyle management and metformin.
Cardiovascular benefits of adding ezetimibe to statin therapy may be greater in patients with diabetes, study finds
Participants were randomized to receive either ezetimibe or placebo in addition to background simvastatin, and the subgroup of patients with diabetes was compared to those without the disease.
A cost-effectiveness analysis found that individualized control saved $13,547 per patient compared with uniform intensive control, primarily due to lower medication costs, and increased quality-adjusted life-years by 0.10.
This month's quiz asks readers to determine appropriate management in a patient with type 2 diabetes during a routine visit.
Recent trials examined the potential effects of probiotic supplements and sucrose octasulfate dressings.
The shock-wave system is intended to be used with standard diabetic ulcer care in patients ages 22 years and older with ulcers lasting more than 30 days.
As an adjunct to diet and exercise, the drug was approved as monotherapy and for use in fixed-dose combinations with metformin or sitagliptin.
The injection is approved to improve glucose control in patients ages three years and older with type 1 diabetes and in adult patients with type 2 diabetes.
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of macroalbuminuria, with measures of renal impairment remaining unchanged.
While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high cardiovascular risk should receive agents with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary.
At the end of 12 months, 36 intervention participants lost 15 kg or more, compared to no participants in the control group, and diabetes remission was associated with the amount of weight lost.